Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810

Mara Colzani, Roberta Noberini, Mauro Romanenghi, Gennaro Colella, Maurizio Pasi, Daniele Fancelli, Mario Varasi, Saverio Minucci, Tiziana Bonaldi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Novel drugs are designed against specific molecular targets, but almost unavoidably they bind non-targets, which can cause additional biological effects that may result in increased activity or, more frequently, undesired toxicity. Chemical proteomics is an ideal approach for the systematic identification of drug targets and off-targets, allowing unbiased screening of candidate interactors in their natural context (tissue or cell extracts). E-3810 is a novel multi-kinase inhibitor currently in clinical trials for its anti-angiogenic and anti-tumor activity. In biochemical assays, E-3810 targets primarily vascular endothelial growth factor and fibroblast growth factor receptors. Interestingly, E-3810 appears to inhibit the growth of tumor cells with low to undetectable levels of these proteins in vitro, suggesting that additional relevant targets exist. We applied chemical proteomics to screen for E-3810 targets by immobilizing the drug on a resin and exploiting stable isotope labeling by amino acids in cell culture to design experiments that allowed the detection of novel interactors and the quantification of their dissociation constant (Kd imm) for the immobilized drug. In addition to the known target FGFR2 and PDGFRα, which has been described as a secondary E-3810 target based on in vitro assays, we identified six novel candidate kinase targets (DDR2, YES, LYN, CARDIAK, EPHA2, and CSBP). These kinases were validated in a biochemical assay and-in the case of the cell-surface receptor DDR2, for which activating mutations have been recently discovered in lung cancer-cellular assays. Taken together, the success of our strategy-which integrates large-scale target identification and quality-controlled target affinity measurements using quantitative mass spectrometry-in identifying novel E-3810 targets further supports the use of chemical proteomics to dissect the mechanism of action of novel drugs.

Original languageEnglish
Pages (from-to)1495-1509
Number of pages15
JournalMolecular and Cellular Proteomics
Volume13
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Proteomics
Phosphotransferases
Assays
Neoplasms
Pharmaceutical Preparations
Receptor-Interacting Protein Serine-Threonine Kinase 2
Tumors
Isotope Labeling
Fibroblast Growth Factor Receptors
Tissue Extracts
Cell Surface Receptors
Cell Extracts
Cell culture
Isotopes
Labeling
Vascular Endothelial Growth Factor A
Mass spectrometry
Toxicity
E-3810
Lung Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry
  • Medicine(all)

Cite this

Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. / Colzani, Mara; Noberini, Roberta; Romanenghi, Mauro; Colella, Gennaro; Pasi, Maurizio; Fancelli, Daniele; Varasi, Mario; Minucci, Saverio; Bonaldi, Tiziana.

In: Molecular and Cellular Proteomics, Vol. 13, No. 6, 2014, p. 1495-1509.

Research output: Contribution to journalArticle

Colzani, Mara ; Noberini, Roberta ; Romanenghi, Mauro ; Colella, Gennaro ; Pasi, Maurizio ; Fancelli, Daniele ; Varasi, Mario ; Minucci, Saverio ; Bonaldi, Tiziana. / Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. In: Molecular and Cellular Proteomics. 2014 ; Vol. 13, No. 6. pp. 1495-1509.
@article{1e88bc71cac64d548859ddbcb71f1bed,
title = "Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810",
abstract = "Novel drugs are designed against specific molecular targets, but almost unavoidably they bind non-targets, which can cause additional biological effects that may result in increased activity or, more frequently, undesired toxicity. Chemical proteomics is an ideal approach for the systematic identification of drug targets and off-targets, allowing unbiased screening of candidate interactors in their natural context (tissue or cell extracts). E-3810 is a novel multi-kinase inhibitor currently in clinical trials for its anti-angiogenic and anti-tumor activity. In biochemical assays, E-3810 targets primarily vascular endothelial growth factor and fibroblast growth factor receptors. Interestingly, E-3810 appears to inhibit the growth of tumor cells with low to undetectable levels of these proteins in vitro, suggesting that additional relevant targets exist. We applied chemical proteomics to screen for E-3810 targets by immobilizing the drug on a resin and exploiting stable isotope labeling by amino acids in cell culture to design experiments that allowed the detection of novel interactors and the quantification of their dissociation constant (Kd imm) for the immobilized drug. In addition to the known target FGFR2 and PDGFRα, which has been described as a secondary E-3810 target based on in vitro assays, we identified six novel candidate kinase targets (DDR2, YES, LYN, CARDIAK, EPHA2, and CSBP). These kinases were validated in a biochemical assay and-in the case of the cell-surface receptor DDR2, for which activating mutations have been recently discovered in lung cancer-cellular assays. Taken together, the success of our strategy-which integrates large-scale target identification and quality-controlled target affinity measurements using quantitative mass spectrometry-in identifying novel E-3810 targets further supports the use of chemical proteomics to dissect the mechanism of action of novel drugs.",
author = "Mara Colzani and Roberta Noberini and Mauro Romanenghi and Gennaro Colella and Maurizio Pasi and Daniele Fancelli and Mario Varasi and Saverio Minucci and Tiziana Bonaldi",
year = "2014",
doi = "10.1074/mcp.M113.034173",
language = "English",
volume = "13",
pages = "1495--1509",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "6",

}

TY - JOUR

T1 - Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810

AU - Colzani, Mara

AU - Noberini, Roberta

AU - Romanenghi, Mauro

AU - Colella, Gennaro

AU - Pasi, Maurizio

AU - Fancelli, Daniele

AU - Varasi, Mario

AU - Minucci, Saverio

AU - Bonaldi, Tiziana

PY - 2014

Y1 - 2014

N2 - Novel drugs are designed against specific molecular targets, but almost unavoidably they bind non-targets, which can cause additional biological effects that may result in increased activity or, more frequently, undesired toxicity. Chemical proteomics is an ideal approach for the systematic identification of drug targets and off-targets, allowing unbiased screening of candidate interactors in their natural context (tissue or cell extracts). E-3810 is a novel multi-kinase inhibitor currently in clinical trials for its anti-angiogenic and anti-tumor activity. In biochemical assays, E-3810 targets primarily vascular endothelial growth factor and fibroblast growth factor receptors. Interestingly, E-3810 appears to inhibit the growth of tumor cells with low to undetectable levels of these proteins in vitro, suggesting that additional relevant targets exist. We applied chemical proteomics to screen for E-3810 targets by immobilizing the drug on a resin and exploiting stable isotope labeling by amino acids in cell culture to design experiments that allowed the detection of novel interactors and the quantification of their dissociation constant (Kd imm) for the immobilized drug. In addition to the known target FGFR2 and PDGFRα, which has been described as a secondary E-3810 target based on in vitro assays, we identified six novel candidate kinase targets (DDR2, YES, LYN, CARDIAK, EPHA2, and CSBP). These kinases were validated in a biochemical assay and-in the case of the cell-surface receptor DDR2, for which activating mutations have been recently discovered in lung cancer-cellular assays. Taken together, the success of our strategy-which integrates large-scale target identification and quality-controlled target affinity measurements using quantitative mass spectrometry-in identifying novel E-3810 targets further supports the use of chemical proteomics to dissect the mechanism of action of novel drugs.

AB - Novel drugs are designed against specific molecular targets, but almost unavoidably they bind non-targets, which can cause additional biological effects that may result in increased activity or, more frequently, undesired toxicity. Chemical proteomics is an ideal approach for the systematic identification of drug targets and off-targets, allowing unbiased screening of candidate interactors in their natural context (tissue or cell extracts). E-3810 is a novel multi-kinase inhibitor currently in clinical trials for its anti-angiogenic and anti-tumor activity. In biochemical assays, E-3810 targets primarily vascular endothelial growth factor and fibroblast growth factor receptors. Interestingly, E-3810 appears to inhibit the growth of tumor cells with low to undetectable levels of these proteins in vitro, suggesting that additional relevant targets exist. We applied chemical proteomics to screen for E-3810 targets by immobilizing the drug on a resin and exploiting stable isotope labeling by amino acids in cell culture to design experiments that allowed the detection of novel interactors and the quantification of their dissociation constant (Kd imm) for the immobilized drug. In addition to the known target FGFR2 and PDGFRα, which has been described as a secondary E-3810 target based on in vitro assays, we identified six novel candidate kinase targets (DDR2, YES, LYN, CARDIAK, EPHA2, and CSBP). These kinases were validated in a biochemical assay and-in the case of the cell-surface receptor DDR2, for which activating mutations have been recently discovered in lung cancer-cellular assays. Taken together, the success of our strategy-which integrates large-scale target identification and quality-controlled target affinity measurements using quantitative mass spectrometry-in identifying novel E-3810 targets further supports the use of chemical proteomics to dissect the mechanism of action of novel drugs.

UR - http://www.scopus.com/inward/record.url?scp=84901950348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901950348&partnerID=8YFLogxK

U2 - 10.1074/mcp.M113.034173

DO - 10.1074/mcp.M113.034173

M3 - Article

C2 - 24696502

AN - SCOPUS:84901950348

VL - 13

SP - 1495

EP - 1509

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 6

ER -